Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2. EG00229 is a neuropilin 1 (NRP1) receptor antagonist.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 438 | 现货 | ||
2 mg | ¥ 642 | 现货 | ||
5 mg | ¥ 1,060 | 现货 | ||
10 mg | ¥ 1,660 | 现货 | ||
25 mg | ¥ 3,180 | 现货 | ||
50 mg | ¥ 4,590 | 现货 | ||
100 mg | ¥ 6,430 | 现货 | ||
500 mg | ¥ 12,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,470 | 现货 |
产品描述 | EG00229 is a neuropilin 1 (NRP1) receptor antagonist that selectively inhibits the binding of VEGF-A to the NRP1 b1 domain, achieving this inhibition with an IC50 value of 3 μM. It does not affect the binding of VEGF-A to other receptors, such as VEGFR-1 and VEGFR-2. |
靶点活性 | Bt-VEGF-A binding to purified NRP1 b1 domain:3 μM , [125I]-VEGF-A binding to PAE/NRP1:8 μM |
体外活性 | EG00229 selectively inhibits radiolabeled 125I-VEGF-A binding to porcine aortic endothelial (PAE)/NRP1, but not VEGFR2-expressing cells, with an IC50 of 8 μM. EG00229 also inhibits VEGF-A binding to lung carcinoma A549 and prostate carcinoma DU145 cells, which express NRP1, but not VEGFR1 and VEGFR2, with similar potency. Binding of VEGF-A to human umbilical vein endothelial cells (HUVECs), which express VEGFR2, VEGFR1, and NRP1, is also inhibited by EG00229 with an IC50 of 23 μM.EG00229 ( 0-100 μM; 48 hours; A549 cells) treatment causes a significant reduction in cell viability over a 48 hours incubation. EG00229 demonstrates inhibition of VEGF-A binding to NRP1 and attenuates VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells is also observed in HUVECs. |
体内活性 | EG00229 treatment substantially reduces tumor growth and visible vascularization. |
分子量 | 611.6 |
分子式 | C19H20F3N7O7S3 |
CAS No. | 1210945-69-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 41.4 mg/mL (67.69 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6351 mL | 8.1753 mL | 16.3506 mL | 40.8764 mL |
5 mM | 0.327 mL | 1.6351 mL | 3.2701 mL | 8.1753 mL | |
10 mM | 0.1635 mL | 0.8175 mL | 1.6351 mL | 4.0876 mL | |
20 mM | 0.0818 mL | 0.4088 mL | 0.8175 mL | 2.0438 mL | |
50 mM | 0.0327 mL | 0.1635 mL | 0.327 mL | 0.8175 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
EG00229 1210945-69-9 Others EG 00229 EG-00229 Inhibitor inhibitor inhibit